Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Phillips 66 — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Phillips 66 trades at $191.94 (market cap $75.52B). The key difference: Phillips 66 is the larger of the two by market cap, and Phillips 66 pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PSX | |
|---|---|---|
Market Cap | $39.89B | $75.52B |
Sector | Health | Energy |
52-Week High | $491.22 | $189.82 |
52-Week Low | $278.09 | $118.37 |
Enterprise Value | $38.15B | $97.49B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Phillips 66 (PSX) trades at $188.36, down 0.77% on the day, with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 18.6 and P/S of 0.57, while recent quarterly earnings have consistently beaten expectations. The company maintains a 14.75% ROE and recently declared a $1.27 quarterly dividend, reflecting management's confidence in cash flow stability.
PSX presents a compelling value opportunity with upside to the $196.57 consensus price target, supported by 57% analyst buy ratings. Key risks include refining margin volatility from Middle East disruptions and declining revenue trends from $170B in 2022 to $132.4B in 2025. The stock's technical overbought condition near resistance at $191 warrants caution despite positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
